Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial

BACKGROUND: The RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, inducing antibodies associated with the prevention of Plasmodium falciparum infection. We assessed the association between anti-circumsporozoite antibody titres and the magnitude and duration of vaccine efficacy using d...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Michael T, Verity, Robert, Griffin, Jamie T, Asante, Kwaku Poku, Owusu-Agyei, Seth, Greenwood, Brian, Drakeley, Chris, Gesase, Samwel, Lusingu, John, Ansong, Daniel, Adjei, Samuel, Agbenyega, Tsiri, Ogutu, Bernhards, Otieno, Lucas, Otieno, Walter, Agnandji, Selidji T, Lell, Bertrand, Kremsner, Peter, Hoffman, Irving, Martinson, Francis, Kamthunzu, Portia, Tinto, Halidou, Valea, Innocent, Sorgho, Hermann, Oneko, Martina, Otieno, Kephas, Hamel, Mary J, Salim, Nahya, Mtoro, Ali, Abdulla, Salim, Aide, Pedro, Sacarlal, Jahit, Aponte, John J, Njuguna, Patricia, Marsh, Kevin, Bejon, Philip, Riley, Eleanor M, Ghani, Azra C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655306/
https://www.ncbi.nlm.nih.gov/pubmed/26342424
http://dx.doi.org/10.1016/S1473-3099(15)00239-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655306/
https://www.ncbi.nlm.nih.gov/pubmed/26342424
http://dx.doi.org/10.1016/S1473-3099(15)00239-X

Ejemplares similares